Drugs and patents in ATC class M01AB - Acetic acid derivatives and related substances

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
CLINORIL	sulindac
SULINDAC	sulindac
TOLECTIN DS	tolmetin sodium
>Tradename	>Generic Name

Last updated: April 25, 2026

How big is the market for ATC M01AB (acetic acid derivatives), and what drives demand?

ATC M01AB is the analgesic/anti-inflammatory therapeutic cluster under topical/systemic NSAIDs and related substances. In market practice, M01AB demand is driven by three recurring commercial variables: formulation access (oral vs topical), payer and guideline placement (step-care and co-morbidity patterns), and local competitive intensity from generics and combination products.

Demand drivers by product type

Demand lever	Mechanism	Typical impact on M01AB economics
Oral vs topical access	Oral NSAIDs face faster generic substitution; topical routes extend life-cycle via formulation differentiation	Higher margin durability for topical branded products; oral brands compress faster
Guideline and OTC adjacency	When products shift toward OTC or pharmacist-led use, volume can stay resilient	Greater volume but lower net price
Co-morbidity and tolerability	Patients with GI risk shift toward topical NSAIDs and lower systemic exposure	Sustained growth pockets for topical diclofenac-like agents within “acetic acid derivative” families
Competition from other NSAID ATCs	Substitution across ATC groups (propionic acids, fenamates, COX-2 selective)	Intensifies pricing pressure across mature active ingredients

Pricing and channel structure (observable pattern in NSAID classes)

Generic-led pricing compresses most oral M01AB-active ingredient categories after patent/market exclusivity expiry.
Formulation innovation (gel/patch systems, optimized penetration, fixed-dose combinations with gastroprotectants or other symptomatic agents where jurisdictional approvals exist) is the main commercial lever to defend unit economics.
Local authorization depth matters. Some jurisdictions allow multiple strengths, pack sizes, and OTC switching, which changes effective market size far more than molecule-level classification.

Which active ingredients define M01AB commercial competition?

ATC M01AB comprises acetic acid derivatives and related substances; in practice, the “center of gravity” is usually occupied by diclofenac products (including salts and formulated variants) and other acetic acid derivative NSAIDs depending on local ATC assignment.

Competitive ingredient map (market-facing)

Active ingredient family	Market role within M01AB	Typical competitive pattern
Diclofenac (and derivatives/salts)	Core volume and prescribing base	High generic penetration; branded pockets persist via formulation, strength/vehicle, and dosing convenience
Other acetic acid derivative NSAIDs under M01AB	Smaller segment relative to diclofenac	Often more limited branded presence; patents concentrate on formulations and specific use/combination

What are the patent landscape characteristics in M01AB?

The M01AB patent landscape is typically dense at the formulation and dosing method level and thin at broad core composition-of-matter after first-wave filings expire. In mature NSAID active ingredients, the most commercially relevant IP often comes from:

Formulation patents (vehicle, penetration enhancers, controlled-release matrices, patches, and gel microstructure)
Salt/form variant patents (when they yield distinct regulatory and commercial positioning)
Combination and dosing regimens (co-administered actives, step-care schedules, or tailored dosing)
Use patents (specific indications, patient subsets, and application regimens), which vary materially in enforceability by jurisdiction

What is the current “freedom-to-operate” shape for M01AB?

For investors and R&D planners, “FTO shape” in M01AB generally follows an NSAID pattern:

Oral products face rapid generic replacement, so new entries depend on either formulation differentiation, new indications, or extended exclusivities in the target jurisdiction.
Topical products often have more room for differentiated claims through transdermal delivery technology and vehicle optimization.
Combination products can be the most IP-visible pathway, but they also require regulatory work and can trigger multi-IP entanglement across both actives.

Where do patent thickets form (by claim type)?

Patent families in M01AB often split into these claim types:

1) Formulation and delivery system claims

Gel/cream microstructure and rheology controls
Penetration enhancer systems and stability regimes
Controlled-release layers and transdermal kinetics

2) Method-of-use claims

Specific dosing schedules
Indication-specific application (e.g., localized pain conditions)
Patient subgroup targeting where supported by clinical data

3) Combination claims

Co-formulated or co-administered products
Fixed-dose regimens

4) Manufacturing process claims

Scale-up steps, sterilization where relevant, and stability-preserving manufacturing conditions

Which patent issuances and filing jurisdictions matter most for M01AB commercialization?

In practice, the relevant competitive patent perimeter concentrates in:

US (ANDA enforcement risk and litigation activity)
EP/WO family coverage via EPO member states (regional injunction leverage)
UK (if targeted for post-Brexit filings)
JP and KR (important for generics and local brand defense)
CN (rapid genericization and local prosecution strategies)

This matters because M01AB products typically trade across multiple markets with the same active but different formulation approvals.

How long do effective exclusivities last in M01AB?

In most mature NSAID categories:

Composition IP typically expires first.
Second-generation formulation IP can extend commercial differentiation for topical and combination SKUs.
Regulatory exclusivities (where applicable) and pediatric or other extension frameworks can extend effective life-cycle, but the main economics shift to the strongest formulation patents.

What is the likely patent strategy used by originators in M01AB?

For brands in acetic acid derivatives (especially diclofenac-like programs), originators tend to:

File incremental formulation families around new vehicles and delivery technologies
Protect specific dosage regimens supported by clinical or PK/PD data
Pursue life-cycle indication and niche use claims where they can support regulatory positioning

For generic entrants:

Design around the specific vehicle/delivery mechanism claims
Avoid claim overlap by using different excipient systems or release profiles
Use regulatory pathways that target non-infringing formulations while meeting bioequivalence and local labeling requirements

What does the patent landscape imply for near-term R&D choices?

The highest probability R&D pathways in M01AB are the same structural places where patents cluster:

Topical delivery systems: new vehicle architectures, improved skin penetration and sustained local exposure
Dosing and regimen optimization: compliant instructions that map to use patents
Combination regimens: careful IP mapping of each active plus the combination-specific formulation

Key Takeaways

M01AB demand is mature and highly price-sensitive for oral products due to generic substitution; topical formulations carry more IP and margin durability.
The patent landscape is structurally formulation-led after early composition-of-matter expiry, with meaningful claim value in vehicle, delivery kinetics, and method-of-use/regimen.
Competitive positioning depends more on jurisdictional patent targeting and formulation design-around than on new core chemistry.
For new entry, the “best odds” are in topical delivery and combination/regimen innovations where measurable differentiators can be defended.

FAQs

1) Which claim types most often remain enforceable in M01AB after generics launch?
Formulation and delivery-system claims (vehicle, penetration, release profile) and specific method-of-use/regimen claims.

2) Why are topical M01AB products usually more IP-visible than oral products?
Topical products can justify distinct vehicle architecture and delivery kinetics tied to local PK/PD and stability, enabling differentiated patent families.

3) What is the typical generic strategy against M01AB brands?
Use regulatory compliance (bioequivalence) while designing around patented formulation/delivery features and avoiding claim scope tied to specific excipient and release mechanisms.

4) Which jurisdictions matter most for competitive IP risk in M01AB?
US and major European coverage are most consequential for enforcement leverage; regional prosecution depth matters for actionable injunction risk.

5) What R&D area has the highest probability of defensible differentiation in M01AB?
New topical delivery systems and dosage regimens that can be tied to measurable performance outcomes supporting patentability.

References

[1] World Health Organization. ATC/DDD index (ATC codes M01AB: Acetic acid derivatives and related substances). https://www.whocc.no/atc_ddd_index/ (accessed 2026-04-25)

Drugs in ATC Class M01AB

Drugs in ATC Class: M01AB - Acetic acid derivatives and related substances

Market dynamics and patent landscape for ATC Class M01AB: Acetic acid derivatives and related substances